Needham & Company Maintains a 'Buy' on Micromet (MITI); Five Things We Like About Micromet – Summary of Company Visit and Management Discussion
Tweet
Share
E-mailGet Alerts MITI Hot Sheet
Price: $0.03 --0%
Rating Summary:
1 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
1 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company maintains a 'Buy' on Micromet (NASDAQ: MITI), PT $13.
Needham analyst says, "Recently, we attended the 2011 EHA Congress where blinatumomab data in r/r ALL were presented for the first time, and we subsequently toured Micromet’s Munich research facility. While we continued to be impressed by the high clinical activity of blinatumomab and believe a second pivotal trial in r/r ALL is on the horizon, we have increased appreciation of the deep science background and BiTE technology platform behind blinatumomab. Key take-ways from our trip included: 1) R/R ALL represents high unmet medical need and substantial market opportunity; 2) Blinatumomab has the potential to change the treatment paradigm in r/r ALL; 3) People and technology platform are the engine for growth; 4) Partnership – brand names now and more expected in the future; and 5) The upside is in the solid tumor space."
For more ratings news on Micromet click here and for the rating history of Micromet click here.
Shares of Micromet closed at $5.48 yesterday.
Needham analyst says, "Recently, we attended the 2011 EHA Congress where blinatumomab data in r/r ALL were presented for the first time, and we subsequently toured Micromet’s Munich research facility. While we continued to be impressed by the high clinical activity of blinatumomab and believe a second pivotal trial in r/r ALL is on the horizon, we have increased appreciation of the deep science background and BiTE technology platform behind blinatumomab. Key take-ways from our trip included: 1) R/R ALL represents high unmet medical need and substantial market opportunity; 2) Blinatumomab has the potential to change the treatment paradigm in r/r ALL; 3) People and technology platform are the engine for growth; 4) Partnership – brand names now and more expected in the future; and 5) The upside is in the solid tumor space."
For more ratings news on Micromet click here and for the rating history of Micromet click here.
Shares of Micromet closed at $5.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- TSS Inc (TSSI) PT Lowered to $13 at Needham
- Nu Holdings (Nubank) (NU) PT Raised to $19 at Needham
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
